The Underground Trail of Retatrutide: A Modern Chapter in Weight-Loss Drug Experimentation
The annals of underground drug use are replete with clandestine societies, where like-minded individuals surreptitiously explore novel compounds to unravel their biological mysteries. From 19th-century Paris, where artists like Baudelaire and Dumas gathered at the Hash Eaters Club to partake of cannabis concentrate, to mid-20th-century California, where chemist Alexander Shulgin hosted gatherings to test psychedelic analogs, such subcultures have long thrived on experimental pharmacology. In 2025, this legacy endures in Jake Terry’s case: a 48-year-old who, seeking to test a novel weight-loss agent, inadvertently triggered a modern underground market for retatrutide, a compound still in clinical trials.
Retatrutide: A "Triple G" Breakthrough in Obesity Treatment
Retatrutide, developed by Eli Lilly, is a non-psychoactive injectable targeting weight loss—a class of drugs including semaglutide (Wegovy) and tirzepatide (Zepbound). Unlike its predecessors, retatrutide acts on three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon (GCG)—earning its "Triple G" moniker.
"These receptors, though chemically related, have unique metabolic roles," explains Richard DiMarchi, professor of chemistry at Indiana University, who pioneered research on this receptor class at Eli Lilly in the late 1990s. "By engineering a single molecule to target all three, retatrutide achieves synergistic effects that outperform individual agents."
In Phase II trials, weekly subcutaneous injections of retatrutide yielded 24.2% mean weight loss over 48 weeks in obese participants—a 6% improvement over tirzepatide (18–20% over 72 weeks) and semaglutide (14.9% over 68 weeks).
The Grey Market: A Lifeline for Uninsured Patients
Terry’s journey began with his daughter, diagnosed with a prolactinoma, which disrupted metabolism and caused weight gain. Facing prohibitive costs for semaglutide ($500/month), Terry sourced tirzepatide from a grey-market pharmacy, achieving success: his daughter lost weight, with Terry crediting the drug for her wedding-day health.
Intrigued, Terry connected with Chinese API manufacturers, discovering retatrutide. He ordered 10 vials (200 mg total), self-administered using Lilly’s trial protocols, and lost 20 pounds in two months. Eager to share, he tested the drug with friends, who reported 12–28 pounds of weight loss. Terry then launched "Compound Sciences," selling retatrutide as "research chemicals" via his Utah-based platform, leveraging a legal loophole: sales to laboratories are lawful, even if repurposed for personal use.
Regulatory Ambiguity and Health Risks
The grey market thrives on high costs and supply shortages of approved weight-loss drugs. "Grey market pharmacies exploit 'research chemical' disclaimers," notes Jesse C. Dresser, a pharmaceutical law partner at Frier Levitt. "The FDA warns against unauthorized sales, as products lack quality verification and pose health risks."
Users like Diana, a new mother with gestational diabetes, reported retatrutide’s appetite-suppressant effects without extreme hunger—a key advantage over competitors. However, adverse effects (fatigue, dizziness, cutaneous hyperesthesia) have been documented, alongside potential drug-alcohol craving reduction, a side effect also seen in GLP-1 agonists.
Eli Lilly’s Phase III Trials and FDA Crackdown
Eli Lilly, which is finalizing Phase III trials, plans FDA approval by late 2026–early 2027. "Retatrutide is intended for patients with severe obesity or obesity-related complications," stated Lilly spokesperson Niki Biro. Terry insists his products are for "research only," despite FDA warnings.
The underground market persists, driven by user demand and Terry’s mission to "make weight-loss treatments accessible." As Phase III data emerges, the ethical and legal future of retatrutide remains uncertain—a cautionary tale of medical innovation unbound by regulation.
Updated 12-16-2025 3:25 pm ET: A correction to Adrian Crook’s concurrent medications was made.